Secondary hyperparathyroidism is a complex endocrine condition characterized by excess circulating parathyroid hormone (PTH) resulting from an underlying condition, most commonly chronic kidney ...

(Reuters) -Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder, sending the Danish drugmaker's shares more than ...

Medically reviewed by Kelly Wood, MD Endocrine disorders happen when hormone levels are too high or too low. Fatigue and mood ...

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S. (Reuters) -The U.S. Food & Drug Administration has extended its review of ...

May 1 (Reuters) - Ascendis Pharma A/S (A71.F), opens new tab said on Monday the U.S. Food & Drug Administration had declined to approve the Danish drugmaker's experimental therapy to treat adult ...

The FDA has extended the target action date by three months to August 14, 2024, from May 14 to provide time for a full submission review. The treatment has already been approved in Europe and Britain ...

(Reuters) -The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday.